| abstract |
The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti -LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention. |